GNC-035

Phase 2Small molecule

SSichuan Baili Pharmaceutical Co., Ltd.

GNC-035 is one of 130 small molecule programs targeting Non-Hodgkins Lymphoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

129

Competitors

Pipeline

Status by Indication[3][1]

Indication

Non-Hodgkins LymphomaRecruiting

Breast CancerActive, not recruiting

Chronic Lymphocytic LeukemiaActive, not recruiting

Refractory Hematologic MalignancyActive, not recruiting

Non-Hodgkins LymphomaPreclinical

Recruiting

Breast CancerPhase 1

Active, not recruiting

Chronic Lymphocytic LeukemiaPhase 2

Active, not recruiting

Refractory Hematologic MalignancyPhase 1

Active, not recruiting

Competition

Competitive Landscape

702 competitors in Breast Cancer

#DrugCompanyPhaseTrials

GNC-035

SSichuan Baili Pharmaceutical Co., Ltd.

Phase 2

1 2

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 3

Vfend

PPrism Pharmaceuticals

Preclinical

—4

Ablavar

LLantheus Medical Imaging

Preclinical

2 5

Tc99m Sestamibi

MM.D. Anderson Cancer Center

Preclinical

2 6

Naltrexone/bupropion

Novo Nordisk

Preclinical

1 7

Sertraline ODT

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 8

Liposomal Irinotecan and Apatinib

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Preclinical

1 9

QS21

MMemorial Sloan Kettering Cancer Center

Preclinical

3 10

Ibrance

Pfizer

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

PreclinicalRecruiting

Non-Hodgkins Lymphoma

NCT06066203

Clinical

Trials by Indication[1]

Refractory Hematologic Malignancy1 trial

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy

Active, not recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 1·NCT05104775·33 enrolled

Chronic Lymphocytic Leukemia1 trial

A Study of GNC-035 in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematological Malignancies

Active, not recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 1/2·NCT05944978·3 enrolled

Breast Cancer1 trial

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Breast Cancer

Active, not recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 1·NCT05160545·36 enrolled

Locally Advanced or Metastatic Solid Tumors1 trial

A Study of GNC-035, a Tetra-specific Antibody, in Participants With Locally Advanced or Metastatic Solid Tumors

Withdrawn·SSichuan Baili Pharmaceutical Co., Ltd.·Phase 1·NCT05039931

Non-Hodgkins Lymphoma1 trial

An Open, Multicenter, Phase I / II Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics / Pharmacodynamics and Antitumor Activity of GNC-035 Tetra-specific Antibody Injection in Relapsed or Refractory Non-Hodgkin 's Lymphoma and Other Hematological Malignancies

Recruiting·SSichuan Baili Pharmaceutical Co., Ltd.·Preclinical·NCT06066203·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for GNC-035. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — GNC-035 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for GNC-035. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sichuan Baili Pharmaceutical Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSichuan Baili Pharmaceutical Co., Ltd.

GNC-035

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Refractory Hematologic Malignancy1 trial

Chronic Lymphocytic Leukemia1 trial

Breast Cancer1 trial

Locally Advanced or Metastatic Solid Tumors1 trial

Non-Hodgkins Lymphoma1 trial

References

Drug Info

Quick Facts

Related News